Company profile: MyOme
1.1 - Company Overview
Company description
- Provider of a comprehensive genetic testing platform, MyOme Personal Genome, using whole genome sequencing to deliver insights into disease risk, medication response, and other health information. Offers Personal Genome reports identifying potential gene mutations and medication responses, and is developing Integrated Personal Risk Score Reports that combine genetic analysis with clinical risk factors for conditions like coronary artery disease and breast cancer.
Products and services
- Integrated Personal Risk Score Reports: Clinically-integrated, upcoming reports combining genetic analysis with clinical risk factors to produce personal risk scores for coronary artery disease and breast cancer
- MyOme Personal Genome™: Whole-genome, comprehensive genetic testing platform that sequences an individual’s entire genome to deliver insights into disease risk, medication response, and other health-related information
- MyOme Personal Genome™ Reports: Gene-level reports architected from the platform that identify potential mutations in genes associated with various conditions and medication responses
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to MyOme
Day Zero Diagnostics
HQ: United States
Website
- Description: Provider of whole-genome sequencing–based tools and services for clinical pathogen detection, antimicrobial resistance profiling, and outbreak management, including Blood2Bac to enrich bacterial DNA directly from blood; Keynome ID for species identification; Keynome gAST for resistance profiling; MicrohmDB to support machine learning; and epiXact for pathogen relatedness insights for infection control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Day Zero Diagnostics company profile →
TwinStrand Biosciences
HQ: United States
Website
- Description: Provider of duplex sequencing technology for DNA sequencing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TwinStrand Biosciences company profile →
PhyNexus
HQ: United States
Website
- Description: Provider of chromatography-enabled pipette tip columns for protein and plasmid purification, delivering high-throughput sample processing for life science researchers in drug discovery, screening, structural studies, and other workflows requiring very pure, highly concentrated products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PhyNexus company profile →
Agena Bioscience
HQ: United States
Website
- Description: Provider of molecular diagnostic genetic reagents and mass spectrometry-based analysis systems, including the MassARRAY System for high-throughput genetic analysis in pharmacogenomics, mutation profiling, liquid biopsy, and inherited disease testing; PGx panels and the VeriDose Core Panel; custom assay services; the Revolution Sample Prep System for cfDNA extraction; and the MassARRAY Insights reporting software network.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Agena Bioscience company profile →
Celmatix
HQ: United States
Website
- Description: Provider of preclinical discovery and development focused on women’s ovarian health, including target identification and validation for endometriosis, PCOS, and ovarian senescence; collaborative discovery, development, and commercialization with Evotec and Bayer; contraceptive target discovery supported by the Bill & Melinda Gates Foundation; and proprietary cohorts, annotations, and NLP-driven research tools.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celmatix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for MyOme
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to MyOme
2.2 - Growth funds investing in similar companies to MyOme
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for MyOme
4.2 - Public trading comparable groups for MyOme
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →